Article contents
Association between IL-17, IL-23 with neurocognitive scales in patients with Alzheimer’s disease
Published online by Cambridge University Press: 13 August 2021
Abstract
Alzheimer’s disease (AD) is a degenerative brain disease and the most common cause of dementia. Evidence suggests that various cytokines, including interleukins (IL) IL-6, IL-10, IL-12 are actively involved in the pathogenesis of AD. The role of IL-17 and IL-23 is less clear.
To investigate the correlations between IL-17, IL-23, and neurocognitive scales in patients with Alzheimer’s disease.
The study included 45 patients: 15 patients with Alzheimer’s disease and 30 patients without cognitive deficit (control group). Clinical and psychometrical methods were used: Mini Mental State Examination (MMSE) scale; Montreal Cognitive Assessment (MoCA), Frontal Assessment Battery (FAB), Alzheimer Disease Assessment Scale-cognitive (ADAS ̶ cog). Serum levels of cytokines of IL-17 and IL-23 were analyzed by sandwich ELISA on “Chem Well 2900” immunoanalyzer (Awareness Technology, USA).
A significantly positive correlation was observed between IL-17 and IL-23 for all AD patients (r =0.723, p=0.002). A significant inverse correlation was observed between serum concentration of IL-17 and MoCA score (r=˗1.0, р≤.0001) and IL-23 and MMSE score (r=˗0.553, р=0.032) in all AD patients. However, no other significant correlations were found between IL-17 and the scores MMSE, FAB, ADAS ̶ cog and between IL-23 and the scores MoCA, FAB and ADAS ̶ cog.
Proinflammatory cytokines (such as IL-17 and IL-23) have been associated with cognitive impairment. However, the complicated relationships of the two cytokines with the pathogenesis of AD need to be further investigated in the future.
No significant relationships.
- Type
- Abstract
- Information
- European Psychiatry , Volume 64 , Special Issue S1: Abstracts of the 29th European Congress of Psychiatry , April 2021 , pp. S718 - S719
- Creative Commons
- This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
- Copyright
- © The Author(s), 2021. Published by Cambridge University Press on behalf of the European Psychiatric Association
- 1
- Cited by
Comments
No Comments have been published for this article.